KN invites shareholders, investors, analysts, and other stakeholders to join its investor conference webinar scheduled on June 14th of 2023 at 9.00 am (EET). The presentation will be held in English. The
New follow-up results from Phase 3 SEQUOIA trial and post hoc safety analyses for BRUKINSA (zanubrutinib) reinforce potential across various B-cell malignancies Early results for BTK-targeted CDAC (BGB-16673)
CHENGDU, China, June 9, 2023 /PRNewswire/ On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 cell) developed by WestVac